Ignite Creation Date:
2025-12-24 @ 10:37 PM
Ignite Modification Date:
2025-12-28 @ 7:10 AM
Study NCT ID:
NCT06229535
Status:
RECRUITING
Last Update Posted:
2024-01-29
First Post:
2023-12-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Right to be Forgotten in the AYA Population: Patients' Experience and Perspectives (Diritto All'Oblio)
Sponsor:
Centro di Riferimento Oncologico - Aviano
Organization:
Study Overview
Official Title:
The Right to be Forgotten in the AYA Population: Patients' Experience and Perspectives (Diritto All'Oblio)
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cancer survivors experience a form of social discrimination that is described in numerous areas such as private life, educational and work paths and the achievement of personal goals. Starting from this scenario, more and more national legislative initiatives are emerging to reconcognize the right to be forgotten, defined as the right not to have to report one's, resolved, oncological disease in contact with institutions such as insurance companies, banks or others. The issue of the right to be forgotten is current and new, primarily in the AYA (adolescents and young adults) population. The purpose of this study is to explore and describe the experience of adolescents and young adults affected by previous oncological disease with respect to the issue of the right to be forgotten. In particular, focusing on:
* awareness (knowledge of the issue);
* significance attributed and subjective perception;
* implications/fallouts perceived or experienced on one's present and future history.
* awareness (knowledge of the issue);
* significance attributed and subjective perception;
* implications/fallouts perceived or experienced on one's present and future history.
Detailed Description:
Cancer survivors experience a form of social discrimination that is described in numerous areas such as private life, educational and work paths and the achievement of personal goals. Starting from this scenario, more and more national legislative initiatives are emerging to reconcognize the right to be forgotten, defined as the right not to have to report one's, resolved, oncological disease in contact with institutions such as insurance companies, banks or others. The issue of the right to be forgotten is current and new, primarily in the AYA (adolescents and young adults) population. The purpose of this study is to explore and describe the experience of adolescents and young adults affected by previous oncological disease with respect to the issue of the right to be forgotten. In particular, focusing on:
* awareness (knowledge of the issue);
* significance attributed and subjective perception;
* implications/fallouts perceived or experienced on one's present and future history.
* awareness (knowledge of the issue);
* significance attributed and subjective perception;
* implications/fallouts perceived or experienced on one's present and future history.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: